Last reviewed · How we verify
GM604
At a glance
| Generic name | GM604 |
|---|---|
| Also known as | GM6, GM602, GM608 |
| Sponsor | Genervon Biopharmaceuticals, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) (PHASE2)
- Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (PHASE2)
- Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GM604 CI brief — competitive landscape report
- GM604 updates RSS · CI watch RSS
- Genervon Biopharmaceuticals, LLC portfolio CI